A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to
evaluate the efficacy, safety, tolerability, and pharmacodynamic effect of subcutaneous
lirentelimab (AK002), given monthly for 6 doses, in subjects with moderate to severe
Eosinophilic Gastritis and/or Eosinophilic Duodenitis who have an inadequate response with,
lost response to, or were intolerant to standard therapies.